Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17113764 | 0.93 | POLB (0.49) | POLBGAASMN1; SMN2HPGDACSS2 | |
| SCHEMBL17315771 | 0.89 | GAA (0.54) | POLBGAASMN1; SMN2HPGDMAPT | |
| SCHEMBL18663971 | 0.88 | GAA (0.45) | POLBGAASMN1; SMN2HPGDACSS2 | |
| SCHEMBL17420744 | 0.87 | POLB (0.44) | POLBGAASMN1; SMN2HPGDACSS2 | |
| SCHEMBL17315773 | 0.86 | GAA (0.51) | POLBGAASMN1; SMN2HPGDACSS2 | |
| SCHEMBL22238291 | 0.83 | POLB (0.41) | POLBGAASMN1; SMN2HPGDACSS2 | |
| SCHEMBL3891001 | 0.82 | KDM4E (0.48) | POLBGAASMN1; SMN2HPGDACSS2 | |
| SCHEMBL161047 | 0.81 | MAPT (0.42) | POLBGAASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL20406093 | 0.81 | KMT2A (0.41) | POLBGAASMN1; SMN2HPGDMAPT | |
| SCHEMBL17118220 | 0.80 | GABRA1 (0.37) | POLBGAASMN1; SMN2HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017494-B2 | Antifungal compound process | Mycovia Pharmaceuticals, Inc. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10000465-B2 | Antifungal compound process | Mycovia Pharmaceuticals, Inc. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170096410-A1 | ANTIFUNGAL COMPOUND PROCESS | Mycovia Pharmaceuticals, Inc. | 2017-04-06 | — | — | US | disclosed |
| US-20170088539-A1 | ANTIFUNGAL COMPOUND PROCESS | Mycovia Pharmaceuticals, Inc. | 2017-03-30 | — | — | US | disclosed |
| US-20170088540-A1 | ANTIFUNGAL COMPOUND PROCESS | Mycovia Pharmaceuticals, Inc. | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017494-B2 | Antifungal compound process | ERG28, DPM1, CYP51A1 | POLB 2744/4885GAA 83/4885SMN1; SMN2 4410/4885 |
| US-10000465-B2 | Antifungal compound process | ERG28, DPM1, CYP51A1 | POLB 2744/4885GAA 83/4885SMN1; SMN2 4410/4885 |
| US-20170096410-A1 | ANTIFUNGAL COMPOUND PROCESS | ERG28, DPM1, CYP51A1 | POLB 2744/4885GAA 83/4885SMN1; SMN2 4410/4885 |
| US-20170088540-A1 | ANTIFUNGAL COMPOUND PROCESS | ERG28, DPM1, CYP51A1 | POLB 2744/4885GAA 83/4885SMN1; SMN2 4410/4885 |
| US-20170088539-A1 | ANTIFUNGAL COMPOUND PROCESS | ERG28, DPM1, CYP51A1 | POLB 2744/4885GAA 83/4885SMN1; SMN2 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.